Advances in the diagnosis and treatment of neuroblastoma

Oncologist

Volumn 8, Issue 3, 2003, Pages 278-292

  Weinstein, Joanna L ^a   Katzenstein, Howard M ^b,c,d   Cohn, Susan L ^a,e  

^a NORTHWESTERN UNIVERSITY   (United States)

^b AFLAC   (United States)

^c CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^d EMORY UNIVERSITY   (United States)

^e CHILDREN'S MEMORIAL HOSPITAL   (United States)

Author keywords

Immunotherapy; Neuroblastoma; Retinoids; Risk based therapy; Tumor biology

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 125; ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTOKINE; CYTOTOXIC AGENT; DISIALOGANGLIOSIDE ANTIBODY; FENRETINIDE; GANGLIOSIDE ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; INTERLEUKIN 2; IRINOTECAN; ISOTRETINOIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 14G.2A; MONOCLONAL ANTIBODY 3F8; MONOCLONAL ANTIBODY CH14.18; NEUROTROPHIN; NEUROTROPHIN RECEPTOR; RETINOIC ACID; RETINOID; TOPOTECAN; UNCLASSIFIED DRUG;

BIOLOGICAL THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SUSCEPTIBILITY; CARDIOPULMONARY INSUFFICIENCY; CHILD; CHILDHOOD CANCER; CLINICAL FEATURE; CLINICAL TRIAL; EARLY MENOPAUSE; ELECTROLYTE DISTURBANCE; GONAD DYSFUNCTION; GROWTH HORMONE DEFICIENCY; HISTOLOGY; HUMAN; HYPOPHYSIS DISEASE; INFERTILITY; KIDNEY TUBULE DISORDER; LEUKEMIA; METASTASIS; MYELODYSPLASIA; NEURAL CREST CELL; NEUROBLASTOMA; ONCOGENE C MYB; OTOTOXICITY; PATIENT CODING; PREDICTION AND FORECASTING; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; SECOND CANCER; SEXUAL MATURATION; THYROID CANCER; THYROID DISEASE;

ADOLESCENT; ADULT; BRAIN NEOPLASMS; CHILD; CHILD WELFARE; CHILD, PRESCHOOL; DISEASE PROGRESSION; HUMANS; INCIDENCE; INFANT; INFANT WELFARE; INFANT, NEWBORN; NEOPLASM STAGING; NEUROBLASTOMA; UNITED STATES;

EID: 0038697907     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.8-3-278     Document Type: Review

References (174)

1. Miller RW, Young JL Jr, Novakovic B. Childhood cancer. Cancer 1994;75(suppl 1):395-405.
2. Brodeur GM, Maris JM. Neuroblastoma. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology, Fourth Edition. Philadelphia: Lippincott-Raven, 2001:895-937.
3. Evans AE, Gerson J, Schnaufer L. Spontaneous regression of neuroblastoma. Natl Cancer Inst Monogr 1976;44:49-54.
4. D'Angio GJ, Evans AE, Koop CE. Special pattern of widespread neuroblastoma with a favourable prognosis. Lancet 1971;1:1046-1049.
5. Haas D, Ablin AR, Miller C et al. Complete pathologic maturation and regression of stage IVS neuroblastoma without treatment. Cancer 1988;62:818-825.
6. Brodeur GM, Seeger RC, Barrett A et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 1988;6:1874-1881.
7. Alvarado CS, London WB, Look AT et al. Natural history and biology of stage A neuroblastoma: a Pediatric Oncology Group study. J Pediatr Hematol Oncol 2000;22:197-205.
8. Perez CA, Matthay KK, Atkinson JB et al. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a Children's Cancer Group study. J Clin Oncol 2000;18:18-26.
9. Bowman LC, Castleberry RP, Cantor A et al. Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study. J Natl Cancer Inst 1997;89:373-380.
10. Schmidt ML, Lukens JN, Seeger RC et al. Biologic factors determine prognosis in infants with stage IV neuroblastoma: a prospective Children's Cancer Group study. J Clin Oncol 2000;18:1260-1268.
11. Matthay KK, Villablanca JG, Seeger RC et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 1999;341:1165-1173.
12. Brodeur GM, Pritchard J, Berthold F et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-1477.
13. Evans AE, D'Angio GJ, Propert K et al. Prognostic factors in neuroblastoma. Cancer 1987;59:1853-1859.
14. Shimada H, Ambros IM, Dehner LP et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999;86:364-372.
15. Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol 1999;17:2264-2279.
16. Sawada T, Hirayama M, Nakata T et al. Mass screening for neuroblastoma in infants in Japan. Interim report of a mass screening study group. Lancet 1984;2:271-273.
17. Nishi M, Miyake H, Takeda T et al. Mass screening of neuroblastoma in Sapporo City, Japan. Am J Pediatr Hematol Oncol 1992;14:327-331.
18. Sawada T, Kidowaki T, Sakamoto I et al. Neuroblastoma. Mass screening for early detection and its prognosis. Cancer 1984;53:2731-2735.
19. Yamamoto K, Hayashi Y, Hanada R et al. Mass screening and age-specific incidence of neuroblastoma in Saitama Prefecture, Japan. J Clin Oncol 1995;13:2033-2038.
20. Kaneko Y, Kanda N, Maseki N et al. Current urinary mass screening for catecholamine metabolites at 6 months of age may be detecting only a small portion of high-risk neuroblastomas: a chromosome and N-myc amplification study. J Clin Oncol 1990;8:2005-2013.
21. Woods WG, Gao RN, Shuster JJ et al. Screening of infants and mortality due to neuroblastoma. N Engl J Med 2002;346:1041-1046.
22. Schilling FH, Spix C, Berthold F et al. Neuroblastoma screening at one year of age. N Engl J Med 2002;346:1047-1053.
23. Gurney JG, Ross JA, Wall DA et al. Infant cancer in the U.S. histology-specific incidence and trends, 1973 to 1992. J Pediatr Hematol Oncol 1997;19:428-432.
24. Ries LAG, Smith MA, Gurney JG et al., eds. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995. Bethesda, MD: National Cancer Institute, 1999:71-72.
25. Maris JM, Kyemba SM, Rebbeck TR et al. Familial predisposition to neuroblastoma does not map to chromosome band 1p36. Cancer Res 1996;56:3421-3425.
26. Kushner BH, Gilbert F, Helson L. Familial neuroblastoma. Case reports, literature review, and etiologic considerations. Cancer 1986;57:1887-1893.
27. Maris JM, Tonini GP. Genetics of familial neuroblastoma. In: Brodeur GM, Sawada T, Tsuchida Y et al., eds. Neuroblastoma, First Edition. Amsterdam: Elsevier Science, 2000:125-135.
28. Castleberry RP, Shuster JJ, Smith EI. The Pediatric Oncology Group experience with the international staging system criteria for neuroblastoma. J Clin Oncol 1994;12:2378-2381.
29. Haase GM, Atkinson JB, Stram DO et al. Surgical management and outcome of locoregional neuroblastoma: comparison of the Childrens Cancer Group and the international staging systems. J Pediatr Surg 1995;30:289-294; discussion 295.
30. Breslow N, McCann B. Statistical estimation of prognosis for children with neuroblastoma. Cancer Res 1971;31:2098-2103.
31. Evans AE, D'Angio GJ, Randolph J. A proposed staging for children with neuroblastoma. Children's Cancer Study Group A. Cancer 1971;27:374-378.
32. Look AT, Hayes FA, Shuster JJ et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 1991;9:581-591.
33. Shimada H, Chatten J, Newton WA Jr et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 1984;73:405-416.
34. Shimada H, Stram DO, Chatten J et al. Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. J Natl Cancer Inst 1995;87:1470-1476.
35. Cohn SL, Rademaker AW, Salwen HR et al. Analysis of DNA ploidy and proliferative activity in relation to histology and N-myc amplification in neuroblastoma. Am J Pathol 1990;136:1043-1052.
36. Brodeur GM, Seeger RC, Schwab M et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224:1121-1124.
37. Seeger RC, Brodeur GM, Sather H et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313:1111-1116.
38. Schweigerer L, Breit S, Wenzel A et al. Augmented MYCN expression advances the malignant phenotype of human neuroblastoma cells: evidence for induction of autocrine growth factor activity. Cancer Res 1990;50:4411-4416.
39. Gross N, Miescher G, Beck D et al. Altered growth and phenotype in clonal mycN transfectants of the SK-N-SH neuroblastoma cell line. Int J Cancer 1994;59:141-148.
40. Schmidt ML, Salwen HR, Manohar CF et al. The biological effects of antisense N-myc expression in human neuroblastoma. Cell Growth Differ 1994;5:171-178.
41. Negroni A, Scarpa S, Romeo A et al. Decrease of proliferation rate and induction of differentiation by a MYCN antisense DNA oligomer in a human neuroblastoma cell line. Cell Growth Differ 1991;2:511-518.
42. Weiss WA, Aldape K, Mohapatra G et al. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 1997;16:2985-2995.
43. Chan HS, Gallie BL, DeBoer G et al. MYCN protein expression as a predictor of neuroblastoma prognosis. Clin Cancer Res 1997;3:1699-1706.
44. Hiyama E, Hiyama K, Yokoyama T et al. Immunohistochemical analysis of N-myc protein expression in neuroblastoma: correlation with prognosis of patients. J Pediatr Surg 1991;26:838-843.
45. Nisen PD, Waber PG, Rich MA et al. N-myc oncogene RNA expression in neuroblastoma. J Natl Cancer Inst 1988;80:1633-1637.
46. Bordow SB, Norris MD, Haber PS et al. Prognostic significance of MYCN oncogene expression in childhood neuroblastoma. J Clin Oncol 1998;16:3286-3294.
47. Cohn SL, London WB, Huang D et al. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. J Clin Oncol 2000;18:3604-3613.
48. Look AT, Hayes FA, Nitschke R et al. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 1984;311:231-235.
49. Taylor SR, Locker J. A comparative analysis of nuclear DNA content and N-myc gene amplification in neuroblastoma. Cancer 1990;65:1360-1366.
50. Bourhis J, DeVathaire F, Wilson GD et al. Combined analysis of DNA ploidy index and N-myc genomic content in neuroblastoma. Cancer Res 1991;51:33-36.
51. Gansler T, Chatten J, Varello M et al. Flow cytometric DNA analysis of neuroblastoma. Correlation with histology and clinical outcome. Cancer 1986;58:2453-2458.
52. Bown N, Cotterill S, Lastowska M et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 1999;340:1954-1961.
53. Fong CT, Dracopoli NC, White PS et al. Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: correlation with N-myc amplification. Proc Natl Acad Sci USA 1989;86:3753-3757.
54. Caron H, van Sluis P, de Kraker J et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 1996;334:225-230.
55. Maris JM, White PS, Beltinger CP et al. Significance of chromosome lp loss of heterozygosity in neuroblastoma. Cancer Res 1995;55:4664-4669.
56. Gehring M, Berthold F, Edler L et al. The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma. Cancer Res 1995;55:5366-5369.
57. Maris JM, Weiss MJ, Guo C et al. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study. J Clin Oncol 2000;18:1888-1899.
58. Guo C, White PS, Weiss MJ et al. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene 1999;18:4948-4957.
59. Maris JM, Guo C, White PS et al. Allelic deletion at chromosome bands 11q14-23 is common in neuroblastoma. Med Pediatr Oncol 2001;36:24-27.
60. Thompson PM, Seifried BA, Kyemba SK et al. Loss of heterozygosity for chromosome 14q in neuroblastoma. Med Pediatr Oncol 2001;36:28-31.
61. Barbacid M. Neurotrophic factors and their receptors. Curr Opin Cell Biol 1995;7:148-155.
62. Brodeur GM, Nakagawara A, Yamashiro DJ et al. Expression of TrkA, TrkB and TrkC in human neuroblastomas. J Neurooncol 1997;31:49-55.
63. Nakagawara A, Arima M, Azar CG et al. Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res 1992;52:1364-1368.
64. Suzuki T, Bogenmann E, Shimada H et al. Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. J Natl Cancer Inst 1993;85:337-384.
65. Nakagawara A, Arima-Nakagawara M, Scavarda NJ et al. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 1993;328:847-854.
66. Kogner P, Barbany G, Dominici C et al. Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor receptor in neuroblastoma with favorable prognosis. Cancer Res 1993;53:2044-2050.
67. Ryden M, Sehgal R, Dominici C et al. Expression of mRNA for the neurotrophin receptor trkC in neuroblastomas with favourable tumour stage and good prognosis. Br J Cancer 1996;74:773-779.
68. Yamashiro DJ, Nakagawara A, Ikegaki N et al. Expression of TrkC in favorable human neuroblastomas. Oncogene 1996;12:37-41.
69. Nakagawara A, Azar CG, Scavarda NJ et al. Expression and function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol 1994;14:759-767.
70. Castleberry RP, Pritchard J, Ambros P et al. The International Neuroblastoma Risk Groups (INRG): a preliminary report. Eur J Cancer 1997;33:2113-2116.
71. Matthay KK, Sather HN, Seeger RC et al. Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy. J Clin Oncol 1989;7:236-244.
72. Kushner BH, Cheung NK, LaQuaglia MP et al. International neuroblastoma staging system stage I neuroblastoma: a prospective study and literature review. J Clin Oncol 1996;14:2174-2180.
73. Nitschke R, Smith EI, Shochat S et al. Localized neuroblastoma treated by surgery: a Pediatric Oncology Group Study. J Clin Oncol 1988;6:1271-1279.
74. Cohn SL, Look AT, Joshi VV et al. Lack of correlation of N-myc gene amplification with prognosis in localized neuro-blastoma: a Pediatric Oncology Group study. Cancer Res 1995;55:721-726.
75. Rubie H, Hartmann O, Michon J et al. N-myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 Study. J Clin Oncol 1997;15:1171-1182.
76. Katzenstein HM, Bowman LC, Brodeur GM et al. Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the Pediatric Oncology Group experience - a Pediatric Oncology Group study. J Clin Oncol 1998;16:2007-2017.
77. Nickerson HJ, Matthay KK, Seeger RC et al. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study. J Clin Oncol 2000;18:477-486.
78. Tonini GP, Boni L, Pession A et al. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children. J Clin Oncol 1997;15:85-93.
79. Ho PT, Estroff JA, Kozakewich H et al. Prenatal detection of neuroblastoma: a ten-year experience from the Dana-Farber Cancer Institute and Children's Hospital. Pediatrics 1993;92:358-364.
80. Saylors RL 3rd, Cohn SL, Morgan ER et al. Prenatal detection of neuroblastoma by fetal ultrasonography. Am J Pediatr Hematol Oncol 1994;16:356-360.
81. Acharya S, Jayabose S, Kogan SJ et al. Prenatally diagnosed neuroblastoma. Cancer 1997;80:304-310.
82. Yamamoto K, Hanada R, Kikuchi A et al. Spontaneous regression of localized neuroblastoma detected by mass screening. J Clin Oncol 1998;16:1265-1269.
83. Holgersen LO, Subramanian S, Kirpekar M et al. Spontaneous resolution of antenatally diagnosed adrenal masses. J Pediatr Surg 1996;31:153-155.
84. Matthay KK, Perez C, Seeger RC et al. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. J Clin Oncol 1998;16:1256-1264.
85. Strother D, van Hoff J, Rao PV et al. Event-free survival of children with biologically favourable neuroblastoma based on the degree of initial tumour resection: results from the Pediatric Oncology Group. Eur J Cancer 1997;33:2121-2125.
86. Kushner BH, Cheung NK, LaQuaglia MP et al. Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy. J Clin Oncol 1996;14:373-381.
87. Matthay KK, Castleberry RP. Treatment of advanced neuroblastoma: the US experience. In: Brodeur GM, Sawada T, Tsuchida Y et al., eds. Neuroblastoma, First Edition. Amsterdam: Elsevier Science, 2000:417-436.
88. Frappaz D, Michon J, Coze C et al. LMCE3 treatment strategy: results in 99 consecutively diagnosed stage 4 neuroblastomas in children older than 1 year at diagnosis. J Clin Oncol 2000;18:468-476.
89. Philip T, Zucker JM, Bernard JL et al. Improved survival at 2 and 5 years in the LMCEI unselected group of 72 children with stage IV neuroblastoma older than 1 year of age at diagnosis: is cure possible in a small subgroup? J Clin Oncol 1991;9:1037-1044.
90. Cheung NK, Heller G. Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J Clin Oncol 1991;9:1050-1058.
91. Kushner BH, LaQuaglia MP, Bonilla MA et al. Highly effective induction therapy for stage 4 neuroblastoma in children over I year of age. J Clin Oncol 1994;12:2607-2613.
92. Kushner BH, O'Reilly RJ, Mandell LR et al. Myeloablative combination chemotherapy without total body irradiation for neuroblastoma. J Clin Oncol 1991;9:274-279.
93. Ladenstein R, Philip T, Lasset C et al. Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol 1998;16:953-965.
94. Philip T, Ladenstein R, Lasset C et al. 1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. European Group for Blood and Marrow Transplant Registry Solid Tumour Working Party. Eur J Cancer 1997;33:2130-2135.
95. Grupp SA, Stem JW, Bunin N et al. Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma. J Clin Oncol 2000;18:2567-2575.
96. Kletzel M, Katzenstein HM, Haut PR et al. Treatment of highrisk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II Study. J Clin Oncol 2002;20:2284-2292.
97. Matthay KK, Atkinson JB, Stram DO et al. Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: a Childrens Cancer Group pilot study. J Clin Oncol 1993; 11:2226-2233.
98. Hoover M, Bowman LC, Crawford SE et al. Long-term outcome of patients with intraspinal neuroblastoma. Med Pediatr Oncol 1999;32:353-359.
99. Plantaz D, Hartmann O, Kalifa C et al. Localized dumbbell neuroblastoma: a study of 25 cases treated between 1982 and 1987 using the same protocol. Med Pediatr Oncol 1993;21:249-253.
100. Traggis DG, Filler RM, Druckman H et al. Prognosis for children with neuroblastoma presenting with paralysis. J Pediatr Surg 1977;12:419-425.
101. King D, Goodman J, Hawk T et al. Dumbbell neuroblastomas in children. Arch Surg 1975;110:888-891.
102. Raffel C. Spinal cord compression by epidural tumors in childhood. Neurosurg Clin N Am 1992;3:925-930.
103. Hayes FA, Thompson EI, Hvizdala E et al. Chemotherapy as an alternative to laminectomy and radiation in the management of epidural tumor. J Pediatr 1984;104:221-224.
104. Ch'ien LT, Kalwinsky DK, Peterson G et al. Metastatic epidural tumors in children. Med Pediatr Oncol 1982;10:455-462.
105. Gutierrez FA, Oi S, McLone DG. Intraspinal tumors in children: clinical review, surgical results and follow-up in 51 cases. Concepts Pediatr Neurosurg 1983;4:291-405.
106. Katzenstein HM, Kent PM, London WB et al. Treatment and outcome of 83 children with intraspinal neuroblastoma: the Pediatric Oncology Group experience. J Clin Oncol 2001;19:1047-1055.
107. Plantaz D, Rubie H, Michon J et al. The treatment of neuroblastoma with intraspinal extension with chemotherapy followed by surgical removal of residual disease. A prospective study of 42 patients - results of the NBL 90 Study of the French Society of Pediatric Oncology. Cancer 1996;78:311-319.
108. Nickerson BG, Hutter JJ Jr. Opsomyoclonus and neuroblastoma: response to ACTH. Clin Pediatr (Phila) 1979;18:446-448.
109. Koh PS, Raffensperger JG, Berry S et al. Long-term outcome in children with opsoclonus-myoclonus and ataxia and coincident neuroblastoma. J Pediatr 1994;125:712-716.
110. Russo C, Cohn SL, Petruzzi MJ et al. Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group. Med Pediatr Oncol 1997;28:284-288.
111. Rudnick E, Khakoo Y, Antunes NL et al. Opsoclonusmyoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies: a report from the Children's Cancer Group Study. Med Pediatr Oncol 2001;36:612-622.
112. Petruzzi MJ, de Alarcon PA. Neuroblastoma-associated opsoclonus-myoclonus treated with intravenously administered immune globulin G. J Pediatr 1995;127:328-329.
113. Nitschke R, Parkhurst J, Sullivan J et al. Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study. J Pediatr Hematol Oncol 1998;20:315-318.
114. Saylors RL 3rd, Stine KC, Sullivan J et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol 2001;19:3463-3469.
115. Athale UH, Stewart C, Kuttesch JF et al. Phase I study of combination topotecan and carboplatin in pediatric solid tumors. J Clin Oncol 2002;20:88-95.
116. Sidell N. Retinoic acid-induced growth inhibition and morphologic differentiation of human neuroblastoma cells in vitro. J Natl Cancer Inst 1982;68:589-596.
117. Reynolds CP, Lemons RS. Retinoid therapy of childhood cancer. Hematol Oncol Clin North Am 2001;15:867-910.
118. Pahlman S, Ruusala AI, Abrahamsson L et al. Retinoic acid-induced differentiation of cultured human neuroblastoma cells: a comparison with phorbolester-induced differentiation. Cell Differ 1984;14:135-144.
119. Thiele CJ, Reynolds CP, Israel MA. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 1985;313:404-406.
120. Finklestein JZ, Krailo MD, Lenarsky C et al. 13-cis-retinoic acid (NSC 122758) in the treatment of children with metastatic neuroblastoma unresponsive to conventional chemotherapy: report from the Childrens Cancer Study Group. Med Pediatr Oncol 1992;20:307-311.
121. Villablanca JG, Khan AA, Avramis VI et al. Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. J Clin Oncol 1995;13:894-901.
122. Lovat PE, Ranalli M, Annichiarrico-Petruzzelli M et al. Effector mechanisms of fenretinide-induced apoptosis in neuroblastoma. Exp Cell Res 2000;260:50-60.
123. Ribatti D, Alessandri G, Baronio M et al. Inhibition of neuro-blastoma-induced angiogenesis by fenretinide. Int J Cancer 2001;94:314-321.
124. Wu ZL, Schwartz E, Seeger R et al. Expression of GD2 ganglioside by untreated primary human neuroblastomas. Cancer Res 1986;46:440-443.
125. Cheung NK, Yu AL. Immunotherapy of neuroblastoma. In: Brodeur GM, Sawada T, Tsuchida Y et al., eds. Neuroblastoma, First Edition. Amsterdam: Elsevier Science, 2000:541-560.
126. Cheung NK, Kushner BH, Kramer K. Monoclonal antibodybased therapy of neuroblastoma. Hematol Oncol Clin North Am 2001;15:853-866.
127. Cheung NV, Lazarus H, Miraldi FD et al. Reassessment of patient response to monoclonal antibody 3F8. J Clin Oncol 1992;10:671-672.
128. Murray JL, Cunningham JE, Brewer H et al. Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol 1994;12:184-193.
129. Handgretinger R, Baader P, Dopfer R et al. A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. Cancer Immunol Immunother 1992;35:199-204.
130. Yu AL, Uttenreuther-Fischer MM, Huang CS et al. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol 1998;16:2169-2180.
131. Kramer K, Gerald WL, Kushner BH et al. Disaloganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma. Med Pediatr Oncol 2001;36:194-196.
132. Barker E, Reisfeld RA. A mechanism for neutrophil-mediated lysis of human neuroblastoma cells. Cancer Res 1993;53:362-367.
133. Munn DH, Cheung NK. Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma. Cancer Res 1987;47:6600-6605.
134. Hank JA, Albertini MR, Schiller J et al. Activation of multiple effector mechanisms to enhance tumor immunotherapy. J Immunother 1993;14:329-335.
135. Frost JD, Hank JA, Reaman GH et al. A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group. Cancer 1997;80:317-333.
136. Haight AE, Bowman LC, Ng CY et al. Humoral response to vaccination with interleukin-2-expressing allogeneic neuroblastoma cells after primary therapy. Med Pediatr Oncol 2000;35:712-715.
137. Brenner MK, Heslop H, Krance R et al. Phase I study of chemokine and cytokine gene-modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma using an adenoviral vector. Hum Gene Ther 2000;11:1477-1488.
138. Ashley DM, Faiola B, Nair S et al. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 1997;186:1177-1182.
139. Worth LL, Jeha SS, Kleinerman ES. Biologic response modifiers in pediatric cancer. Hematol Oncol Clin North Am 2001;15:723-740.
140. Favrot M, Floret D, Michon J et al. A phase-II study of adoptive immunotherapy with continuous infusion of interleukin-2 in children with advanced neuroblastoma. A report on 11 cases. Cancer Treat Rev 1989;16(suppl A):129-142.
141. Rueda F, Marti F, Pardo N et al. Interleukin-2 in neuroblastoma: clinical perspectives based on biological studies. Cancer Biother Radiopharm 1996;11:303-308.
142. Pardo N, Marti F, Fraga G et al. High-dose systemic interleukin-2 therapy in stage IV neuroblastoma for one year after autologous bone marrow transplantation: pilot study. Med Pediatr Oncol 1996;27:534-539.
143. Becker JC, Varki N, Gillies SD et al. An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. Proc Natl Acad Sci USA 1996;93:7826-7831.
144. 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol 1998;16:229-236.
145. 131I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients. Br J Cancer 1999;81:1378-1384.
146. Yanik GA, Levine JE, Matthay KK et al. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol 2002;20:2142-2149.
147. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
148. Meitar D, Crawford SE, Rademaker AW et al. Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol 1996;14:405-414.
149. Eggert A, Ikegaki N, Kwiatkowski J et al. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res 2000;6:1900-1908.
150. Nagabuchi E, VanderKolk WE, Une Y et al. TNP-470 antian-giogenic therapy for advanced murine neuroblastoma. J Pediatr Surg 1997;32:287-293.
151. Wassberg E, Pahlman S, Westlin JE et al. The angiogenesis inhibitor TNP-470 reduces the growth rate of human neuro-blastoma in nude rats. Pediatr Res 1997;41:327-333.
152. Katzenstein HM, Rademaker AW, Senger C et al. Effectiveness of the angiogenesis inhibitor TNP-470 in reducing the growth of human neuroblastoma in nude mice inversely correlates with tumor burden. Clin Cancer Res 1999;5:4273-4278.
153. Davidoff AM, Leary MA, Ng CY et al. Gene therapy-mediated expression by tumor cells of the angiogenesis inhibitor flk-1 results in inhibition of neuroblastoma growth in vivo. J Pediatr Surg 2001;36:30-36.
154. Shusterman S, Grupp SA, Barr R et al. The angiogenesis inhibitor TNP-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease. Clin Cancer Res 2001;7:977-984.
155. Moller TR, Garwicz S, Barlow L et al. Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries. J Clin Oncol 2001;19:3173-3181.
156. Mertens AC, Yasui Y, Neglia JP et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol 2001;19:3163-3172.
157. Giantris A, Abdurrahman L, Hinkle A et al. Anthracyclineinduced cardiotoxicity in children and young adults. Crit Rev Oncol Hematol 1998;27:53-68.
158. Krischer JP, Epstein S, Cuthbertson DD et al. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol 1997;15:1544-1552.
159. Meadows AT, Tsunematsu Y. Late effects of treatment for neuroblastoma. In: Brodeur GM, Sawada T, Tsuchida Y et al., eds. Neuroblastoma, First Edition. Amsterdam: Elsevier Science, 2000:561-570.
160. Rossi R, Godde A, Kleinebrand A et al. Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients. J Clin Oncol 1994;12:159-165.
161. Friedman DL, Meadows AT. Late effects of childhood cancer therapy. Pediatr Clin North Am 2002;49:1083-1106.
162. Cohen LE. Endocrine late effects of cancer treatment. Curr Opin Pediatr 2003;15:3-9.
163. Kushner BH, Cheung NK, Kramer K et al. Neuroblastoma and treatment-related myelodysplasia/leukemia: the Memorial Sloan-Kettering experience and a literature review. J Clin Oncol 1998;16:3880-3889.
164. Tucker MA, Jones PH, Boice JD Jr et al. Therapeutic radiation at a young age is linked to secondary thyroid cancer. The Late Effects Study Group. Cancer Res 1991;51:2885-2888.
165. Hann HW, Levy HM, Evans AE. Serum ferritin as a guide to therapy in neuroblastoma. Cancer Res 1980;40:1411-1413.
166. Silber JH, Evans AE, Fridman M. Models to predict outcome from childhood neuroblastoma: the role of serum ferritin and tumor histology. Cancer Res 1991;51:1426-1433.
167. Shuster JJ, McWilliams NB, Castleberry R et al. Serum lactate dehydrogenase in childhood neuroblastoma. A Pediatric Oncology Group recursive partitioning study. Am J Clin Oncol 1992;15:295-303.
168. Zeltzer PM, Marangos PJ, Sather H et al. Prognostic importance of serum neuron specific enolase in local and widespread neuroblastoma. Prog Clin Biol Res 1985;175:319-329.
169. Comito MA, Savell VH, Cohen MB. CD44 expression in neuroblastoma and related tumors. J Pediatr Hematol Oncol 1997;19:292-296.
170. Combaret V, Gross N, Lasset C et al. Clinical relevance of CD44 cell-surface expression and N-myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas. J Clin Oncol 1996;14:25-34.
171. Combaret V, Lasset C, Frappaz D et al. Evaluation of CD44 prognostic value in neuroblastoma: comparison with the other prognostic factors. Eur J Cancer 1995;31A:545-549.
172. Norris MD, Bordow SB, Marshall GM et al. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med 1996;334:231-238.
173. 5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide. Cancer Res 2000;60:712-721.
174. Ribatti D, Surico G, Vacca A et al. Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with progression in human neuroblastoma. Life Sci 2001;68:1161-1168.